Primary mediastinal B-cell lymphoma (PMBL) is a specific subtype of diffuse large B-cell lymphoma with a distinctive clinical course and a specific genetic profile.^[@bib1],[@bib2]^ Several prior studies have provided key molecular--genetic aberrations;^[@bib1],[@bib3]^ however, a targeted next-generation sequencing-based study of relevant oncogenes in all currently available PMBL cell lines has not been performed. Here we report previously unrecognized mutations in known hot-spot regions of the *KIT* oncogene in \~12.5% of PMBL tumors. Interestingly, activating mutations in the proto-oncogene *KIT* have already been described in a variety of malignancies, including mast cell leukemia, acute myelogenous leukemia, gastrointestinal stromal tumors, as well as several other solid tumors,^[@bib4]^ where they carry, in part, therapeutic relevance due to clinically effective inhibitors.^[@bib5],[@bib6]^

We performed next-generation sequencing-based screening of all three available PMBL cell lines using a panel of 50 relevant oncogenes (see [Supplementary material](#sup1){ref-type="supplementary-material"} and [Supplementary Table 1](#sup1){ref-type="supplementary-material"}). The full list of sequence alterations is provided in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}. Notably, we found *KIT* mutations in two of three PMBL cell lines that we confirmed by Sanger sequencing ([Figure 1](#fig1){ref-type="fig"}). Given that these alterations were present at previously described hot spots, we further determined the mutation frequency in primary tumor samples using our PMBL cohort.^[@bib7]^ We found three missense mutations in 30 tumor samples (10%). One of these samples (PMBL.1) was the parental tumor, from which we derived the Med-B1 cell line,^[@bib8]^ thereby confirming that the *KIT* mutation is indeed present in the primary tumor and is not a result of genomic cell culture permutation. DNA analysis from microdissected non-tumor tissue in two of the mutated tumor samples showed wild-type sequence and confirmed the mutations as somatic.

Regarding the prevalence of *KIT* mutations in PMBL, we had to take the duplicate sample Med-B1 and parental tumor (PMBL.1) into account; we found a total of five mutations in 32 tested samples and determined a mutation frequency of \~15.6% in our cohort. When further restricting these calculations to missense mutations, we excluded sample PMBL.29 that harbored only a sense mutation (c.2394 C\>T; p.I798I); the overall frequency of missense *KIT* mutations in PMBL (4 of 32 different samples) surmounts to \~12.5% ([Figure 1](#fig1){ref-type="fig"}). Besides this relatively high prevalence of *KIT* mutations, interestingly, all detected *KIT* missense mutations in PMBL are rare. Three mutations have been previously reported in other tumors ([Table 1](#tbl1){ref-type="table"}), and affect amino acids located in the activation loop (p.809--823) of the kinase domain ([Supplementary Figure 1](#sup1){ref-type="supplementary-material"}). One mutation (p.C788Y) is located in the kinase domain and has not been reported before. Notably, all four *KIT* missense mutations in PMBL are classified as 'damaging\' by several *in silico* prediction tools and have therefore a possible impact on protein function ([Table 1](#tbl1){ref-type="table"}). This is also suggested by previous functional studies investigating missense mutations at these genetic hotspot regions of *KIT*.^[@bib9],\ [@bib10],\ [@bib11]^ Thus, our findings collectively suggest the possibility of specific diagnostic, prognostic and therapeutic implications of *KIT* mutations in PMBL.

Notably, a recent genome-wide study delineated the mutational landscape in PMBL,^[@bib3]^ but missed the striking frequency of over 10% recurrent *KIT* mutations in PMBL. Arguably, this genome-wide study was performed according to very high standards, sufficient coverage and expert bioinformatics analysis. Nonetheless, their approach was to initially sequence two PMBL patient samples, and further experiments---including targeted sequencing of one identified gene in a larger number of samples---were made based on the findings in these two patient samples. Thus, despite the advents of genome-wide analyses, the imposed sampling bias precluded identification of recurrent *KIT* mutations in PMBL. Pointing this out should in no way compromise the importance of revealing the mutational spectrum of PMBL; however, our data paradigmatically prove the existence of false negatives in these large-scale data sets.^[@bib12],\ [@bib13],\ [@bib14]^ Furthermore, our data---albeit at a much smaller sequencing scale---emphasize targeted re-sequencing as an effective approach to perform high-throughput genotyping in tumor samples.^[@bib14],[@bib15]^ In summary, we report for the first time that \~12.5% of PMBL samples harbor mutations in the *KIT* oncogene.
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![*KIT* mutations in primary mediastinal B-cell lymphoma. Key clinico-pathological features of individual samples (columns) along with genotyping result from the next-generation oncopanel and traces from confirmational Sanger sequencing. Mut., mutant; WT, wild type.](bcj201461f1){#fig1}

###### *KIT* mutations in primary mediastinal B-cell lymphoma

                             *K1106*  *U-2940*                     *MedB-1* [a](#t1-fn1){ref-type="fn"}   *PMBL.19*                    *PMBL.24*                                            *PMBL.29*           
  ------------------------- --------- ---------------------------- -------------------------------------- ---------------------------- ---------------------------------------------------- ------------------- ------------------------
  Nucleotide substitution      ---    c.2446G\>A                   c.1621A\>C                             c.2440G\>A                   c.2467T\>A                                           c.2363G\>A          c.2394C\>T
  Amino-acid change            ---    p.D816N                      p.M541L                                p.A814T                      p.Y823N                                              p.C788Y             p.I798I
  SIFT score                   ---    Damaging 0.1                 Tolerated 0.6                          Damaging 0                   Damaging 0                                           Damaging 0          ---
  PolyPhen-2                   ---    Probably damaging            Benign                                 Probably damaging            Probably damaging                                    Probably damaging   ---
  COSMIC                       ---    NK-T cell lymphoma (*N*=1)   *N*=31                                 Mast cell neoplasm (*N*=1)   Colorectal cancer (*N*=2); germ cell tumor (*N*=1)   ---                 *N*=12
  EVS                          ---    ---                          AA=5327, CA=1110, CC=66                ---                          ---                                                  ---                 CC=6190, TC=303, TT=10

Abbreviations: COSMIC, catalogue of somatic mutations in cancer (<http://cancer.sanger.ac.uk/cancergenome/projects/cosmic>, last accessed 30 March 2014); Dam., damaging; EVS, exome variant server (<http://evs.gs.washington.edu/EVS>), containing a data set comprising 2203 African-American and 4300 European-American unrelated individuals; PolyPhen-2, prediction of functional effects of an amino-acid substitution (<http://genetics.bwh.harvard.edu/pph2>); Prob. dam., probably damaging; SIFT, sorts intolerant from tolerant (<http://sift.jcvi.org/>); Tol., tolerated.

Note that the mutation in the MedB-1 cell line was also present in the parental tumor that the cell line was derived from (PMBL.1; see also [Figure 1](#fig1){ref-type="fig"}).
